Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets
Koner, Jasdip S. and Rajabi-Siahboomi, Ali R. and Missaghi, Shahrzad and Kirby, Daniel and Perrie, Yvonne and Ahmed, Jiteen and Mohammed, Afzal R. (2019) Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets. Scientific Reports, 9 (1). 12467. ISSN 2045-2322 (https://doi.org/10.1038/s41598-019-48859-x)
Preview |
Text.
Filename: Koner_etal_SR_2019_Conceptualisation_development_fabrication_and_in_vivo_validation_of_a_novel_disintegration_tester_for_orally_disintegrating_tablets.pdf
Final Published Version License: Download (1MB)| Preview |
Abstract
Disintegration time is the key critical quality attribute for a tablet classed as an Orally Disintegrating Tablet (ODT). The currently accepted in vitro testing regimen for ODTs is the standard United States Pharmacopeia (USP) test for disintegration of immediate release tablets, which requires a large volume along with repeated submergence of the dosage form within the disintegration medium. The aim of this study was to develop an in vivo relevant ODT disintegration test that mimicked the environment of the oral cavity, including lower volume of disintegration medium, with relevant temperature and humidity that represent the conditions of the mouth. The results showed that the newly developed Aston test was able to differentiate between different ODTs with small disintegration time windows, as well as between immediate release tablets and ODTs. The Aston test provided higher correlations between ODT properties and disintegration time compared to the USP test method and most significantly, resulted in a linear in vitro/in vivo correlation (IVIVC) (R2 value of 0.98) compared with a "hockey stick" profile of the USP test. This study therefore concluded that the newly developed Aston test is an accurate, repeatable, relevant and robust test method for assessing ODT disintegration time which will provide the pharmaceutical industry and regulatory authorities across the world with a pragmatic ODT testing regime.
-
-
Item type: Article ID code: 69998 Dates: DateEvent28 August 2019Published7 August 2019AcceptedSubjects: Medicine > Therapeutics. Pharmacology Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 01 Oct 2019 11:01 Last modified: 19 Nov 2024 21:41 URI: https://strathprints.strath.ac.uk/id/eprint/69998